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Background: Gene-directed enzyme prodrug therapy (GDEPT) represents a technology to improve drug selectivity
for cancer cells. It consists of delivery into tumor cells of a suicide gene responsible for in situ conversion of a
prodrug into cytotoxic metabolites. Major limitations of GDEPT that hinder its clinical application include inefficient
delivery into cancer cells and poor prodrug activation by suicide enzymes. We tried to overcome these constraints
through a combination of suicide gene therapy with immunomodulating therapy. Viral vectors dominate in
present-day GDEPT clinical trials due to efficient transfection and production of therapeutic genes. However,
safety concerns associated with severe immune and inflammatory responses as well as high cost of the
production of therapeutic viruses can limit therapeutic use of virus-based therapeutics. We tried to overcome
this problem by using a simple nonviral delivery system.
Methods: We studied the antitumor efficacy of a PEI (polyethylenimine)-PEG (polyethylene glycol) copolymer
carrying the HSVtk gene combined in one vector with granulocyte–macrophage colony-stimulating factor (GM-CSF)
cDNA. The system HSVtk-GM-CSF/PEI-PEG was tested in vitro in various mouse and human cell lines, ex vivo and in vivo
using mouse models.
Results: We showed that the HSVtk-GM-CSF/PEI-PEG system effectively inhibited the growth of transplanted human
and mouse tumors, suppressed metastasis and increased animal lifespan.
Conclusions: We demonstrated that appreciable tumor shrinkage and metastasis inhibition could be achieved with a
simple and low toxic chemical carrier – a PEI-PEG copolymer. Our data indicate that combined suicide and cytokine
gene therapy may provide a powerful approach for the treatment of solid tumors and their metastases.
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Chemotherapy, radiotherapy and surgery are conventional
treatments for cancer (for recent review, see [1,2]). How-
ever, chemotherapy and radiotherapy agents are highly
hazardous and, in addition, a majority of cancers have
become resistant to current therapeutic options [1,2].
This makes the development of more efficient strategies
highly desirable. Various inter- and intracellular barriers
to tumor-targeted chemotherapeutic drugs have been con-
sidered in detail [3-6].
Great attention was also paid to a strategy of antican-
cer therapy aimed to potentiate antitumor activity of the
immune system [7-12], that looks highly promising.
More than 15 years ago the anticancer armamentarium
was extended with gene therapy approaches, the develop-
ment of which has dramatically accelerated in the recent
years (see [13], and for recent reviews [1,2,14-16]). Many
approaches to cancer gene therapy have been proposed,
and viral and nonviral vectors have been explored. Various
strategies of gene therapy have been described (for most
recent reviews, see [1,2]. One of them (the suicide gene/
prodrug approach or gene directed enzyme prodrug gene
therapy, GDEPT) [1,2,14,17-19] is targeted at the systems
common to all cancer cells, usually at the replication sys-
tem. In this regard, this approach resembles chemotherapy
with its universal applicability to different types of cancer.
However, suicide gene therapy hits its targets from within
the cancer cell and is therefore expected to be less toxic to
normal cells than classic chemotherapy. GDEPT (other
synonyms of this technology see in [19]) is based on the
delivery into cancer cells of expressible genes encoding
enzymes that can metabolize a separately administered
nontoxic prodrug into a cytotoxin. This makes the system
much safer than any other known tumor- targeting sys-
tems. The generated cytotoxin can not only kill the cancer
cell where it was produced but also diffuse into neighbor-
ing cells and kill them. This is a so called bystander effect
[20-23]. Bystander cell killing may greatly increase the effi-
ciency of GDEPT.
In general, GDEPT looks essentially more powerful
than molecular targeted approaches, and recent reports
on pre-clinical cancer models demonstrated a high poten-
tial of this strategy [1]. Several enzyme-prodrug systems
are now in preclinical and clinical trials [1], including the
most extensively studied systems of the herpes simplex
virus thymidine kinase gene (HSVtk) with ganciclovir
(GCV) as a prodrug, and the cytosine deaminase gene
(CD) of Escherichia coli or yeast which converts the non-
toxic antifungal agent 5-fluorocytosine (5-FC) into toxic
5-fluorouracil (5-FU).
Major limitations of the suicide gene therapy that
hinder its clinical application include inefficient deliv-
ery to cancer cells (it is also the problem for chemothera-
peutic targeting) and poor prodrug activation by suicideenzymes [14]. Some efforts have been and are currently
being pursued to increase the activity of individual suicide
enzymes towards their respective prodrugs ([24] and refs.
therein).
Another way to overcome these constraints might be
to combine suicide gene therapy with immunomodulating
therapy. Many cytokines activate the immune system, in-
cluding interleukins (IL) 2, 4, 7, 12 and 18, interferon γ
(IFN-γ), tumor necrosis factor α (TNF-α), and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF),
which are among the most potent inducers of anti-tumor
activity in a variety of preclinical studies [25-27]. However,
it was reported that effects of cytokines are contradictory
and depend on the tumor type and disease stage. More-
over, some cytokines can facilitate malignization of tumors
and metastasizing [28,29]. Therefore, the choice of cyto-
kines for gene-therapeutic purposes should be based on
a thorough analysis of their tests as antitumor agents.
Such an analysis indicated that one of the promising
candidates was GM-CSF. A comparison of various cy-
tokines showed that GM-CSF enhanced most types of
immune responses [30].
It is important that recombinant GM-CSF (Sargramostim)
has been extensively used in cancer patients, and its safety
is thus well established [31]. Several species of oncolytic
viruses were armed with GM-CSF and tested in clinical
trials. The trials supported antitumor efficacy of GM-CSF
and tumor-specific immune activation [26,31-35]. GM-
CSF-secreting vaccines for solid tumors demonstrated
promising evidence of safety in early phase clinical testing
[36,37]. An oncolytic adenovirus coexpressing IL-12 and
GM-CSF in combination with vaccination demonstrated
synergistic antitumor effects [38].
A combination of HSVtk in an adenoviral vector with
another vector carrying both the GM-CSF and IL-2 genes
was tested. The results obtained demonstrated that coex-
pression of GM-CSF and IL-2 could enhance the effect
of HSVtk suicide gene therapy [39]. Other studies also
confirmed the efficacy of using IL-2 and GM-CSF in
combination with HSVtk in adenoviral vectors [40].
Also, a combination of GM-CSF and HSVtk gene ther-
apy showed a greater therapeutic effect than HSVtk
alone [41,42].
However, there is some uncertainty about the use of
GM-CSF as an agent for the induction of antitumor
immunity [43-45]. GM-CSF may play a key role in the
appearance of host immune cells with a suppressive pheno-
type that poses a significant problem to successful therapy
for metastatic cancers [46-48]. To explain the successful
antitumor role of GM-CSF in combination with suicide
genes, it was suggested that when tumor cells are destroyed
and release tumor-specific antigens, GM-CSF in the tumor
microenvironment increases antigen uptake and presenta-
tion by antigen presenting cells [31,41].
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mor activity of oncolytic viruses armed with GM-CSF
[26,32,49-54]. Therefore, a combination of cancer cell
destroying agents with GM-CSF can be a powerful tool
for killing cancer and metastasis cells. Up to now, all such
combinations used viral vectors that have some limitations
in their application to clinical practice [2,55].
To our knowledge, the present study is the first one to
test the efficacy of an HSVtk/GM-CSF combination in
one vector using a nonviral system (a PEG-PEI copoly-
mer) for its delivery. Nonviral vectors are advantageous
over viral vectors due to low immunogenicity, practically
unlimited packaging capacity for genetic material, as well
as simple and low-cost production [56]. They are used as
components of self-assembling complexes with anionic
DNA (‘polyplexes’). Among cationic polymers, polyethyle-
nimine (PEI) attracts special attention and is the most
intensively studied polymer for gene-therapy purposes.
The properties and behavior of PEI-containing poly-
plexes, modified with polyethylene glycol (PEG) and
the cell-penetrating peptide TAT, in different cell lines
can be adjusted to achieve higher transfection effi-
ciency [57].
Here, the system was tested in vitro in various cell
lines, ex vivo, and in vivo on mouse models, and promis-
ing results were obtained.
Materials and methods
Construction of expression plasmids
The cDNA of the hGM-CSF gene was amplified from
plasmid hGM-CSF-pBK, (kindly provided by S. Larin, IGB
RAS, Moscow) using primers 5′-TTATCGATATGTGGC
TGCAGAGC and 5′-TTGGATCCTCACTCCTGGACT
GG that had at their 5′-ends the restriction sites of ClaI
and BamHI, respectively. The amplificate was ligated into
pAL-TA vector (Evrogen, Moscow, Russia) containing an
SV40 polyA fragment. The hGM-CSF-polyA sequence
was excised with ClaI and SphI and cloned into retroviral
vector pFB-neo (Stratagene, La Jolla, USA) that contained
a picornavirus internal ribosome entry site (IRES) and wasFigure 1 Schematic representation of the expression constructs used
the schemes. CMV – major immediate-early promoter of human cytomega
granulocyte macrophage colony stimulating factor, respectively; HSVtk
entry site of encephalomyocarditis virus.hydrolyzed by these restriction endonucleases. The IRES-
hGM-CSF-polyA cassette was excised from this vector
with NotI and BamHI, and its ends were filled in with
Klenow fragment. After this, the cassette was blunt-end
ligated into CMV-HSVtk-pGL3 vector [58], split at a
unique site by XbaI and treated with Klenow fragment.
This gave the construct CMV-HSVtk-hGM-CSF-pGL3
(designated as TKhGM, Figure 1) harboring the HSVtk
and hGM-CSF genes under the control of the CMV
promoter.
To obtain the construct CMV-HSVtk-mGM-CSF-pGL3
(designated as TKmGM, Figure 1), the mGM-CSF cDNA
was amplified with primers 5′-TTATCGATATGTGGCT
GCAGAAT and 5′-TTGGATCCTCATTTTTGGCC that
had at their 5′-ends the restriction sites of ClaI and
BamHI, respectively. The amplified fragment was cloned
into the construct CMV-HSVtk-hGM-CSF-pGL3 split
with ClaI and BamHI.
The design of such constructions was reported earlier [59].
Cell cultures
The following cancer cell lines were used: HEK293 (trans-
formed human kidney cells), HT1080 (human fibrosar-
coma), A431 (human epidermoid carcinoma), and Calu1
(human epidermoid lung carcinoma) from ECACC
(Salisbury, UK), and C26 (murine colon adenocarcinoma)
from Cell Lines Service (CLS GmbH, Eppelheim, Germany).
Sarcoma 37, Lewis lung carcinoma (LLC), and cervical
squamous carcinoma (CSC5) mouse tumors were ob-
tained from the Department of Tumor Strains of Blokhin
RRCO RAMS (Moscow, Russia).
Tumor cell lines LLC, CSC5 и S37 were obtained by
culturing dissociated cells from the corresponding trans-
plantable mouse tumors in RPMI 1640 medium.
S37, CSC5 and C26 cell lines were grown in RPMI1640
medium containing 12.5% fetal calf serum, 60 μg/ml peni-
cillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphoteri-
cin at 37°C and 5% CO2.
All other cells were grown in DMEM/F12 medium
containing 10% fetal calf serum, 60 μg/ml penicillin,. On the left – construct names. The SV40 polyA signal is omitted from
lovirus; hGM-CSF and mGM-CSF – human and mouse genes of
–herpes simplex virus thymidine kinase gene, IRES - internal ribosome
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37°C and 5% CO2.
All materials for cell culturing were obtained from
Invitrogen (Carlsbad, CA, USA).
DNA transfection
Lipofection
For transfection, cells were seeded into 24-well plates or
25-см3 flasks and incubated in serum-containing medium
for 24 h. Cells were transfected with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s recommendations. After this, the transfected cells
were cultured for 48 h at 37°С and 5% CO2.
For the GM-CSF protein quantification using ELISA
and Western-blot analysis, the transfection was performed
in 25-cm3 flasks for 48 h.
Transfection with a PEI-PEG-TAT copolymer
A polyethylenimine (PEI)-polyethylene glycol (PEG)-TAT
peptide copolymer (PPT) was obtained as described previ-
ously [57]. In this study, the ratio of PEI to PEG in polyplexes
was optimized according to [57] to achieve maximum trans-
fection efficiency. A DNA-PPT complex was obtained by
vigorous mixing of one volume of a PEI-PEG-TAT copoly-
mer in 0.1 M borate (pH 7.5), one volume of 20% glucose,
20 мМ HEPES buffer (pH 7.4), and two volumes of plas-
mid DNA water solution (160 μg/ml DNA). The resulting
solution contained 80 μg/ml DNA and 12.8 μg/ml co-
polymer. The mixture was incubated for 1–2 h at room
temperature and used for injection into animals in in vivo
experiments. Cells were transfected in 24-well plates with
the resulting solution 20-40-fold diluted (depending on
the cell line) with growth medium and added to wells in a
volume of 1 mL per well. The transfected cells were cul-
tured for 72 h at 37°С and 5% CO2, and further incubated
for 24 h at 37°С and 5% CO2 after addition of an equal
volume of nutrient medium.
All plasmids used for transfection were isolated using
an EndoFree Plasmid Maxi Kit (Qiagen, Valencia, CA).
Measurement of transfection efficiency
To determine transfection efficiency, reporter plasmids
carrying the EGFP reporter gene driven by the pCMV
immediate early promoter were used. Cells were trans-
fected in 24-well plates with Lipofectamine 2000 (LFA)
or PEI-PEG-TAT. In 48 h after transfection with LFA or
72 h in the case of PPT, cells were photographed on a
Nikon fluorescence microscope (200 × field) at 395-nm
excitation, and the number of fluorescent cells was deter-
mined in 10 microscopic fields. Cells were further washed
with PBS buffer, detached from the plate surface with
trypsin, and suspended in PBS at 106 cells per 1 ml. The
percentage of transfected cells was determined using a
fluorescence-activated cell sorter FACS Scan Analyzer(BD Bioscience, San-Jose, CA). The data were processed
using BD CellQuest Pro (BD Bioscience, San-Jose, CA)
and WinMDI 2.8 (by Joe Trotter) software. The trans-
fection efficiency was determined as the percentage of
cells whose fluorescence intensity exceeded that of non-
transfected cells.
In vitro cell sensitivity to ganciclovir
Transfected cells were detached from the plate surface,
seeded into 96-well plate at 1500-2000 cells per well and
incubated for 12–18 h at 37°С and 5% CO2. The wells
were then supplemented with ganciclovir Cymevene®
(F. Hoffman-La Roche Ltd, Switzerland) solution up to
final concentrations of 12.5, 50 or 200 μM, and incubated
for 48 h, after which the GCV solution was replaced with
a fresh one, and cells were additionally incubated for 48 h.
The number of viable cells was determined by the MTS
assay according to the protocol (CellTiter 96® Aqueous
One Solution Cell Proliferation Assay, Promega, Madison,
WI). The results were expressed as a ratio between the
number of viable cells in the plates that contained the
drug and their number in the corresponding drug-free
controls. Three independent transfections were performed
in each experiment.
HSVtk and GM-CSF production by transfected cells
The transfected cells were lyzed in SDS sample buffer,
and proteins were separated on a 10% SDS-PAGE and
transferred into PVDF membranes. A goat polyclonal
antiserum against HSVtk (Santa Cruz Biotechnology,
Santa Cruz, CA) and donkey anti-goat IgG-horseradish
peroxidase conjugates (Santa Cruz, CA, USA) were used
to visualize thymidine kinase. Detection of reactive bands
was facilitated by using a horseradish peroxidase-linked
secondary conjugate and ECL detection reagents (Biorad,
USA).
mGM-CSF and hGM-CSF produced by transfected cells
were measured by ELISA of culture medium using a com-
mercial kit (R&D Systems, Minneapolis, MN).
Measurement of the biological activity of hGM-CSF
The biological activity of hGM-CSF was determined by
the ability of hGM-CSF-containing conditioned medium
to maintain proliferation of the hGM-CSF-dependent
erythroleukemia cell line TF-1 [60].
Measurement of the biological activity of mGM-CSF
The biological activity of mGM-CSF was estimated by
the ability of GM-CSF-containing conditioned medium
to initiate differentiation of mouse bone marrow precur-
sor cells. The precursor cells were cultured in medium
supplemented with conditioned medium obtained from
S37 cells treated with TKmGM-PPT. As a negative con-
trol, we used conditioned medium obtained from S37
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and mGM-CSF genes without promoter and was com-
plexed with a PPT copolymer. The procedure was per-
formed as described in [61]. The cells were stained with
FITC-labeled antibodies (Caltag, Buckingham, UK) spe-
cific for F4/80 (a marker of mature macrophages), IAd
(an innate activation marker of macrophages and den-
dritic cells), and Gr-1 (a marker of granulocytes), or with
PE (phykoerythrin)-labeled antibodies against CD86 (a
marker of mature dendritic cells). The stained cells were
cytofluorometrically analyzed for the presence of differ-
entiated cells.
Ex vivo experiments
In ex vivo experiments, we used C57Bl/6 mice (Animal
Breeding Facility - Branch of Shemyakin & Ovchinnikov
Institute of Bioorganic Chemistry, Puschino, Moscow
Region, Russia) with an initial medium body weight of
19.0 ± 1.4 g.
LLC cells were transfected with the CMV-HSVtk-pGL3
(designated as TK) and TKmGM constructs, whereas
non-transfected cells were used as the control. The trans-
fection was performed for 3 h at 30 μg DNA and 75 μl
Lipofectamine 2000 (LFA) per 75-cm3 flask. In 24 h after
transfection, the transformed and non-transformed LLC
cells were detached with 3 ml trypsin per flask, suspended
in complete DMEM/F12 medium, washed twice with PBS,
and suspended in PBS at 2 × 106 cells/ml. 100-μl aliquots
(2 × 105 cells) of the suspension were subcutaneously
injected into the right dorsal flank of animals. Start-
ing from day 6 after inoculation and after the appearance
of palpable tumors, tumor size was measured using an
electronic caliper.
Tumor volume was calculated using the formula А*В2/2
[62], where A and B is the length and width of the tumor,
respectively. An euthanasia criterion was the tumor size
that has reached 2000 mm3.
Each test group of animals injected with LLC cells
transformed with the TK and TKmGM constructs con-
tained 10 animals. Control groups contained 6 animals
and were injected with non-transformed LLC cells. Ani-
mals were uniformly divided among the groups accord-
ing to their weight.
The average size of tumors was calculated as the total
tumor volume divided by the number of animals in the
group. The measurement was done until the death of the
first animal in each group.
Survival rate of mice was determined as the ratio of
the number of mice, having no tumor or tumor with a
volume less than 2000 mm3, to the total number of mice
in the group. The calculations were carried out until the
death of the last mouse with tumor.
5 mg/ml GCV in PBS buffer (Invitrogene, Carlsbad,
CA, USA) was intraperitoneally injected into animals for10 days, two times a day in a dose of 75 mg/kg, starting
from the second day (48 h) after transplantation of car-
cinoma cells.
In vivo experiments
Six- to eight-week-old F1 (С57Bl/6j × CBA), BDF1, and
BALB/c mice were obtained from the Research Centre
of Biomedical Technologies, RAS. All animal protocols
were performed in accordance with the “Guidelines to
Carry out Preclinical Trials of Pharmaceuticals” [62],
and the experiments were approved by the Bioethical
Committee of the Moscow Hertsen Research Institute of
Oncology (MHRIO).
In these experiments we used the TK, mGM and TKmGM
constructs complexed with the PEI-PEG-TAT copolymer
(designated as TK-PPT, mGM-PPT and TKmGM-РРT,
respectively) or with LFA (TK-LFA, mGM-LFA and
TKmGM-LFA, respectively). In the case of PPT, the ani-
mals were injected with a 80 μg/ml DNA and 12.8 μg/ml
copolymer solution. For LFA, the injected solution con-
tained 2.5 μl LFA per 1 μg DNA.
The DNA-PPT/GCV system was injected into animals
of the experimental groups at the doses and according
to the schedule described in the Results and Discussion
section. Control animals were injected with either pure
buffer or DNA-PPT and GCV separately at the same doses
and according to the same schedule. Each group con-
tained 8–12 animals, and each experiment was repeated
in triplicate.
The mouse S37, LLC and cervical squamous carcin-
oma (CSC5) tumor strains were maintained in syngeneic
mice using standard methods. Tumor cells of the 2nd-
8th passages were used in vivo. The C26 colon adenocar-
cinoma cells were maintained using standard protocols.
The tumor cells or tissues were subcutaneously (s.c.)
injected into mice at the following doses per mouse:
Sarcoma 37 (F1 С57Bl/6j × CBA mice) - 2 × 106 cells,
С26 (BALB/c mice) - 4 × 104 cells, LLC (BDF1 mice) –
30 mg of tumor tissue, CSC5 (BDF1 mice) - 20 mg of
tumor tissue in 0.1 ml of isotonic (0.9%) NaCl solution.
Primary tumors were formed in 90-100% of animals. They
had standard growth patterns, and S37 also had the ability
to form metastases.
Evaluation of antitumor and antimetastatic efficacy
was based on measuring the tumor volumes of the pri-
mary and metastatic nodes, the lifespan of animals and
frequency of lymphogenic metastasis in different groups.
The tumor growth delay (TGD, days) was calculated by
the formula:
TGD = TTEexp–TTEcont, where
TTEexp and TTEcont are the periods of achieving a cer-
tain tumor volume in the experimental and control
groups, respectively. The reference tumor volume varied
for different tumors from 500 mm3 for S37 (TGD500) to
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3 for C26
(TGD1500).
Tumor metastasis inhibition (MI,%) was calculated by
the formula:
MI ¼ Vmts cð Þ−Vmts expð ÞVmts cð Þ  100%, where
Vmtsc – mean volume of metastatic lymph nodes in
the control groups,
Vmtsexp – mean volume of metastatic lymph nodes in
the experimental group.
Frequency of lymphogenic metastasis (FLM,%) was
calculated by the formula:
FLM ¼ MT  100%, where
M – the number of animals in the group that had me-
tastases in lymph nodes,
T – the total number of animals in the group.
The presence of metastatic tumor cells in the enlarged
lymph nodes of tumor bearing mice was proven using
histological examination of the dissected tissues. The
lymph nodes were dissected at autopsy, measured in
three cross dimensions by a caliper, fixed in 10% neutral
buffered formalin, and embedded into paraffin. Tissue
sections stained by haematoxylin and eosin were
examined.
The increase in lifespan (ILS,%) was calculated by the
formula:
ILS ¼ MLS expð Þ−MLS cð ÞMLS cð Þ  100%, where
MLS(exp) – mean lifespan in the experimental group
(days),
MLS(c) – mean lifespan in the control groups (days).
Statistical analysis
Statistical analysis was performed using Statistical soft-
ware version 7.0 (StatSoft, Inc.). The statistical signifi-
cance of differences between groups was estimated using
the t-Student test, Fisher’s test and the Mann–Whitney
U-criterion depending on the number of observations
and the distribution of parameter values in the group.
The differences were considered significant at p < 0.05.
Survival data were presented as Kaplan-Meier curves.
Results
Construction and in vitro properties of IRES vectors for
coexpression of the HSVtk and GM-CSF genes
We constructed a series of expression plasmids in which
the human cytomegalovirus (CMV) major immediate-early
promoter directed the expression of the single or tandemly
linked HSVtk and GM-CSF genes. Since the GM-CSF pro-
tein is species-specific, and the efficacy of gene therapeutic
constructs was tested in tumor-inoculated animals, we pre-
pared two constructs, one of which contained the mouse
gm-csf gene (mGM-CSF) and was designed for model ex-
periments in mice, whereas another one contained human
GM-CSF and was designed for testing of toxicity andsubsequent clinical trials as well as for comparative ana-
lysis of the functional properties of human and mouse
GM-CSF containing constructs.
Simultaneous expression of two genes under the con-
trol of one promoter was enabled by the insertion of the
internal ribosome entry site (IRES) between the genes.
The structure of the vectors constructed is presented
in Figure 1. Each vector contained either the single
genes or their tandem combination under the control of
the CMV promoter.
Transient transfection experiments showed that the
expression level of the HSVtk and mouse and human
GM-CSF genes within bicistronic expression constructs
obtained was close to that in the constructs containing
single genes (Additional file 1: Figure S1).
HEK293 cells transfected with the TKhGM construct
produced 110 ng hGM-CSF per 106 cells a day, whereas
transfected with the control plasmid CMV-hGM-CSF-
pGL3 (designated as hGM) – 115 ng, and transfected
with TKmGM and CMV-hGM-CSF-pGL3 (designated as
mGM) – 182 and 190 ng mGM-CSF, respectively. Con-
ditioned medium obtained from non-transfected cells
did not contain GM-CSF indicating that GM-CSF was
produced only due to the expression of the GM-CSF
gene within the vectors obtained.
Estimations of the HSVtk biological activity revealed
that incubation with GCV was equally efficient in killing
cells transfected both with TK and TKmGM (Additional
file 2: Figure S2).
The human and mouse GM-CSF protein produced by
the expression vectors was found to be biologically ac-
tive (data not shown).Use of the PEG-PEI-TAT copolymer for delivery of genetic
information into cancer cells: comparison with
lipofectamine
Transfection of cell lines in vitro was performed using a
standard procedure with LFA. However, the use of LFA
as part of gene therapeutic systems is limited due to its
toxicity and high price.
In this work, we used polyplexes based on polyethyle-
nimine (PEI) conjugated with a heterobifunctional PEG
derivative (N-hydroxisuccinimide ester maleimido-PEG-
24) to make the complex more hydrophilic. To facilitate
penetration into cells, the TAT cell-penetrating peptide
(GRKKKRRQRC) was attached to the PEI-PEG copoly-
mer [57,63]. The efficiency of transfection of cancer cells
of different origin with PEG-PEI-TAT (PPT) and LFA
was compared using a GFP reporter gene. The percent-
age of cells transfected using PPT depended on the cell
type and was in a range of 25-45% for S37 cells, 30-40%
for C26, 20-45% for A431, about 20% for HT1080, and 5-
30% for LLC cells. For the same cell lines, the transfection
Figure 2 Effect of ex vivo transformation of LLC cells with the
TK and TKmGM constructs combined with administration of
GCV on A) tumor growth rate, and B) animal lifespan after
transplantation of the transfected cells into C57Bl/6 mice.
The data represent mean values for treatment groups of ten animals
and control groups of six animals. We studied 6 groups of mice: two
control groups (K/GCV and K/PBS) inoculated with non-transfected
cells; two experimental groups (TK/GCV and TK/PBS) inoculated with
LLC cells transfected with TK; and two experimental groups (TKmGM/
GCV and TKmGM/PBS) inoculated with LLC cells transfected with
TKmGM using LFA. The animals of groups К/GCV, ТK/GCV and
TKmGM/GCV received intraperitoneal injections of ganciclovir in a
dose of 75 mg/kg twice a day for 10 days. The animals of groups К/PBS,
ТK/PBS and TKmGM/PBS received phosphate buffered saline (PBS) as a
placebo instead of GCV. Starting from day 6 after transplantation, we
measured the volume of developed tumors. The euthanasia criterion
was the tumor volume that exceeded 2000 mm3. A) Tumor volume
(in mm3, Y-axis) versus time since cell transplantation (X-axis). Mean ±
SEM values are shown. B) Survival period of mice after transplantation
of the transfected and non-transfected LLC cells.
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Also, it was shown that in С26, A431 and НT1080
cell lines the cytotoxic effect of the TKhGM-PPT or
TKmGM-PPT complex with GCV was weaker than
that of TKGM-LFA, whereas in S37 cells the cytotoxic
effects of TKGM-PPT and TKGM-LFA were compar-
able (Additional file 3: Table S1) .
It is important to note that the in vivo antitumor effi-
cacies of LFA and PPT deliveries were approximately the
same.
Our experiments demonstrated that TGD, the lifespan,
MI and FLM were almost equal for TKmGM and TK
constructs combined with GCV irrespective of the used
delivery system - LFA or PPT (See Additional file 4:
Table S2, Additional file 5: Figure S3). The reason of this
phenomenon is under investigation, but probably the
known enhanced permeability and retention effect [4] is
somehow involved.
Ex vivo antitumor efficacy of TK/GCV and TKmGM/GCV
To evaluate the contribution of GM-CSF to the thera-
peutic potential of the prepared constructs, the antitu-
mor efficacy of the TK and TKmGM construct was
measured ex vivo in C57BI/6 mice. The mice were sub-
cutaneously inoculated with LLC cells transiently trans-
fected with the TK or TKmGM construct using LFA.
We studied 3 groups of mice: a group inoculated with
non-transfected LLC cells (group K), a group inoculated
with LLC cells transfected with the TK construct (group
TK), and a group inoculated with LLC cells transfected
with TKmGM (group TKmGM). Then, half of the ani-
mals from each group were intraperitoneally injected
with GCV solution at a dose of 75 mg/kg twice a day for
10 days (groups K/GCV, TK/GCV and TKmGM/GCV),
whereas the second half were injected with phosphate
buffered saline (PBS) as placebo control (groups K/PBS,
TK/PBS and TKmGM/PBS).
As seen from Figure 2A, on day 18 of the experiment
(the last day when all animals were still alive), the ani-
mals inoculated with the TKmGM/GCV or TK/GCV
system showed no indications of tumor development.
The tumor growth in the group of animals inoculated with
the TKmGM/PBS combination was markedly slower than
that in the TK/PBS group or control groups, and the dif-
ference was statistically significant (p < 0.05). Since the an-
imals inoculated with TKmGM/PBS or TK/PBS received
phosphate buffered saline (PBS) instead of GCV, the sup-
pression of tumor growth in the TKmGM/PBS group was
most probably due to the presence of the GM-CSF gene.
On day 18 of the experiment, the mean tumor volume in
the K/GCV control group exceeded that in the K/PBS
control group, however, the difference was not statistically
significant (p = 0.262).By the end of the experiment (on day 60), all animals
from the TKmGM/GCV group were alive, whereas 10 and
50% of the animals from the TK/GCV and TKmGM/PBS
groups, respectively, have died. All mice of the TK/PBS,
PBS, and GCV groups died (Figure 2В). All animals that
have survived by day 60 of the experiment did not pro-
duce recurrent tumors during an one-year period of ob-
servation after the end of the experiment. Thus, both the
TK and TKmGM constructs demonstrated antitumor
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in the case of TKmGM. This experiment was repeated
in triplicate, and in all cases the survival rate in the
TKmGM/GCV group was higher than that in the TK/
GCV group.
Similar results were obtained earlier in the work of
Castleden et al., where the authors in ex vivo experi-
ments compared antitumor effects of a construct, in
which the HSVtk and GM-CSF genes shared a common
promoter, and of constructs harboring the single HSVtk
or GM-CSF genes [64].
Further comparative analysis of the therapeutic poten-
tial of the constructs was performed in vivo in mice.Tumor growth delay and prolongation of the survival period
due to TKmGM-PPT/GCV therapy of tumor-bearing mice
We used PEG-PEI-TAT (PPT) copolymers for in vivo
delivery of the therapeutic constructs obtained [57,65].
We showed that the developed copolymers are non-
immunogenic and can be easily modified for targeted
delivery (to be published separately).Table 1 Effect of intratumoral administration of various comp
A) Scheme of administration
B)
Constructs and controls Lifespan, days ILS,% TGD500mm3
TKmGM-PPT/GCV 60 ± 22 70* 14.1
TK-PPT/GCV 57 ± 15 62* 11.6
mGM-PPT/GCV 39 ± 13 9 4.1
TKmGM-PPT/PBS 41 ± 7 16 3.9
TK-PPT/PBS 38 ± 4 8 2.6
mGM-PPT/PBS 48 ± 4 35 3.0
Control/GCV 40 ± 3 6 0.3
Control/PBS 35 ± 3 -
F1 (С57Bl/6jxCBA) female mice (12 animals in each group) were inoculated with sar
(CMV-HSVtk-pGL3), mGM (CMV-mGM-CSF-pGL3); PPT - polyethylenimine-polyethyle
GCV – ganciclovir. Control - the group that received only GCV or PBS. Administratio
intravenously twice a day with an interval of 12 h in a daily dose of 150 mg/kg for 15 d
FLM - frequency of lymphogenic metastasis, MI –metastasis process inhibition, mean v
PBS) and the volume of lymph nodes were measured on day 30 after inoculation. The
interval between administrations. PBS was administered in volumes equivalent to the
constructs was 25 μM.
*- statistically significant values (p < 0.05).The selection of the most efficient therapeutic
scheme for the copolymer/DNA polyplexes obtained
was done using F1 С57Bl/6j x CBA mice subcutane-
ously inoculated with sarcoma 37 cells. These cells were
characterized by the highest level of transfection with
the polyplexes.
The most efficient therapeutic scheme for TKmGM-
РРТ/GCV was found to be triple intratumoral injection
of TKmGM-РРТ at a unit dose of 0.04 μg DNA per
1 mm3 tumor volume with 5-day intervals (Table 1А) at
the background of GCV injection for 15 days.Comparison of the antitumor effect of the TK, mGM and
TKmGM constructs delivered by PEG-PEI-TAT in mice with
sarcoma 37
Mouse sarcoma 37 cells were subcutaneously inoculated
into F1 С57Bl/6j x CBA mice. The treatment according to
the scheme in Table 1А was started on day 7 of tumor
growth, when the mean tumor volume was about 100 mm3.
We used polyplex solutions at PPT concentrations in a
range of 12.5-25 μM, because we have earlier shown thatlexes on mice inoculated with sarcoma 37
, days FLM,% Volume of lymph nodes, mm
3 MI,%
33* 100 ± 45 82*
58* 186 ± 80 67*
50* 189 ± 91 66
42* 298 ± 264 47
75 459 ± 339 18
58* 349 ± 242 38
100 457 ± 121 19
100 562 ± 316
coma 37 on day zero. TKmGM (CMV-HSVtk-mGM-CSF-pGL3 construct), TK
ne glycol-TAT peptide copolymer; PBS – phosphate buffered saline (placebo);
ns of the complexes are shown by arrows in the scheme. GCV was administered
ays (total dose 2.25 g/kg). ILS –increase in lifespan, TGD –tumor growth delay,
alues. ILS, FLM, MI (compared with the control group of animals that received
constructs and control solutions were administered intratumorally with a 5-day
GCV administration scheme. The PPT concentration in injected solutions of the
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within this range (data not shown).
As seen from Table 1 and Figure 3, intratumoral injec-
tions of the TK/GCV or TKmGM/GCV polyplexes had a
biologically significant antitumor effect. On day 30, the ex-
tension of animal lifespan in mice treated with TKmGM/
GCV and TK/GCV was as high as 70 and 62%, respectively.
The tumor growth delay (TGD500) for the combination
TKmGM/GCV was 14.1 days, and for the combination
TK/GCV – 11.6 days.
At the same time, injection of the mGM/GCV, TKmGM/
PBS, TK/PBS or mGM/PBS combinations without GCV or
solely GCV had an insignificant effect on tumor growth
and animal lifespan.Comparison of the antimetastatic effect of the TK, GM
and TKmGM constructs delivered by PEG-PEI-TAT in
mice with sarcoma 37
Transplantable mouse sarcoma 37 is characterized by
extensive lymphogenic metastasis. According to our
observations, popliteal and inguinal lymph nodes are
the first to be affected by metastases in a mouse bear-
ing the tumor implanted subcutaneously in a hind
paw. The inguinal lymph nodes are preferable for S37
metastasis assessment because the popliteal lymph
nodes are often involved into the area of the primary
tumor growth.
Progressive growth of S37 tumor in mice was accom-
panied by an increase in the regional lymph nodes size.
The mean volume of the inguinal lymph nodes in nor-
mal C57Bl/6j × CBA mice was found to be 16 ± 6 mm3.
The mean volume of ipsilateral and contralateral lymphFigure 3 Survival of S37-bearing mice after injection of TK-PPT,
mGM-PPT and TKmGM-PPT with or without ganciclovir. TKmGM
(CMV-HSVtk-mGM-CSF-pGL3 construct), TK (CMV-HSVtk-pGL3), mGM
(CMVmGM-CSF-pGL3); PPT - polyethylenimine-polyethylene glycol-TAT
peptide copolymer; PBS – phosphate buffered saline (placebo);
GCV – ganciclovir.nodes measured on day 35 of the tumor growth in mice
bearing subcutaneous S37 tumor varied from 350-
500 mm3 to 120-200 mm3, respectively.
The presence of metastatic tumor cells in the enlarged
lymph nodes of tumor bearing mice was proven using
histological examination of the dissected tissues. The ex-
tent of involment of lymph nodes, as a rule, correlated
with their size. In the lymph nodes with the volume less
than 100 mm3 dissected on day 30–35 after tumor in-
oculation, the area occupied by metastatic cells usually
did not exceed 20%. Microfoci of tumor cells or single
tumor cells could be revealed (the estimation was made
using serial sections). For the nodes with a 100–250 mm3
volume, the involved section area varied from 20 to 75%.
In lymph nodes with a larger volume, metastatic tumor
usually completely replaced the lymph node parenchyma.
Thus, we consider the volume of inguinal lymph nodes in
sarcoma 37 bearing mice a satisfactory and convenient
surrogate marker for tumor metastasis assessment.
The total volume of bilateral regional ipsilateral plus
contralateral lymph nodes was measured in mice bearing
transplanted sarcoma 37. There are two limitations of
such a nodes volume-based approach. First, its sensitiv-
ity is insufficient to detect early stages of metastasis. Sec-
ond, the size of the affected lymph nodes does not
always correspond to the amount of metastatic tumor
cells because of possible reactive changes. Nevertheless,
changes in the mean volume of mouse inguinal lymph
nodes in the experimental groups directly and strongly
correlated with primary S37 tumor growth and lifespan
of animals in all our experiments.
The bilateral inguinal lymph nodes of each mouse bear-
ing sarcoma 37 were histologically examined to reveal
metastatic involvement at the end of the surveillance
period. Histological structure of the primary tumor and
typical histological findings in the tissues of dissected
lymph nodes are represented in Figure 4 (see a-c, e-g).
It was shown that the volume of lymph nodes in the
groups of animals that received TKmGM, TK and mGM
polyplexes combined with GCV was much smaller than
that in the control group or the comparison groups
(Table 1B). The highest metastasis inhibition (82%) was
observed in mice that received TKmGM/GCV, whereas
in the case of TK/GCV and mGM/GCV this inhibition
was 67 and 66%, respectively. In the groups of animals
treated with the constructs without GCV, metastasis in-
hibition was observed only for the TKmGM and mGM
constructs (47 and 38%, respectively). This is in line with
literature data on the essential role of GM-CSF in me-
tastasis inhibition [41,64]. The data obtained demon-
strated that the most efficient metastasis inhibition
(high MI and low FLM) could be achieved with a com-
bination of the HSVtk and GM-CSF genes within one
construct.
Figure 4 Histological images of tumors and lymph nodes. Subcutaneously transplanted mouse sarcoma 37 on day 15 of tumor growth
(a,d). Metastatic ipsilateral inguinal lymph nodes on the day 30 of tumor growth in control mice (b,c,f,g). Images show tumor cells infiltrating
lymph node parenchyma (f) and totally replacing lymph node tissue (g). A lymph node taken on day 30 after the beginning of the treatment
from a mouse treated with TKmGM/GCV (h); note that its parenchyma is free of tumor cells. The sections are made through the largest cross
dimension of the tissue samples. Low-power field images (a-d, 40×) demonstrate differences in size between positive (metastatic) and negative
(metastasis free) lymph nodes. High-power field images (e-h, 400×) represent detailed histological features of the specimens. Formalin fixed and
paraffin embedded tissues (H&E staining).
Table 2 Effect of administration of the TKmGM-PPT complex




ILS% TGD1500 days ILS% TGD1000 days
TKmGM-PPT/GCV 42 8.5 20 6.0
TKmGM-PPT/PBS −4 −0.3 - -
Control/GCV −12 0.8 0 −0.1
Control/PBS - - - -
C26 – female BALB/c mice with C26 tumor (groups of 10 animals), CSC5 –
female BDF1 mice with CSC5 tumor (groups of 18 animals). Control – the
group that received only GCV or PBS. The complexes were administered
intratumorally 3 times in a single dose of 0.04 μg DNA/mm3 of tumor volume
with a 5-day interval. The first administration was on day 7 of tumor growth.
GCV – ganciclovir; GCV was administered for 15 days intraperitoneally twice a
day with an interval of 12 h in a daily dose of 150 mg/kg (total dose of 2.25
g/kg). ILS –increase in lifespan of mice, TGD –tumor growth delay, MI –metastasis
inhibition, mean values, FLM – frequency of lymphogenic metastasis (percentage
of animals with metastases in lymph nodes). ILS and MI were measured on day
30 of tumor growth. PBS was administered in volumes equivalent to the GCV
administration scheme.
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PPT/GCV system in different tumors
The therapeutic potential of the constructs in combin-
ation with GCV was evaluated in allograft mouse models
inoculated with C26 (murine colon adenocarcinoma)
and CSC5 (cervical squamous carcinoma) tumors.
Carcinoma CSC5 tumors were subcutaneously inocu-
lated into F1 (С57Bl/6j x CBA) mice, and adenocarcinoma
of the mouse large intestine (С26) was also subcutaneously
inoculated into BALB/c mice. The treatment was started
on day 7 of tumor growth, when the mean volume of
tumor was about 100 mm3. The constructs were injected
directly into tumors at a dose of 0.04 μg DNA/mm3 three
times with 5-day intervals. GCV was administered for
15 days as intravenous infusions twice a day at a daily dose
of 100 mg/kg for F1 mice and 150 mg/kg for BALB/c mice.
The data obtained showed (Table 2, Figure 5) that
treatment with TKmGM-PPT plus GCV had a biologic-
ally significant antitumor effect in animals with C26 tu-
mors. On day 26 in the case of C26 ILS was 42%.
TGD1500 in the animals with С26 was 8.5 days. In the
case of CSC5 we observed TGD1000 equal to 6 days and
a modest or even biologically insignificant extension of
animal lifespan (23%). It may be due to the specific
properties of CSC5 tumor or to a non-optimal scheme
of treatment for this type of cancer. Injection of con-
structs without GCV or solely GCV did not appreciably
affect tumor growth.
Thus, treatment of sarcoma 37-bearing mice with
TKmGM-PPT/GCV according to the scheme used is ef-
fective with respect to both the primary tumor focus(TGD 14.1 days) and metastasis (MI 82%, at the criter-
ion of 35%, FLM 33%) (Table 1, Figure 3). These effects
extended the lifespan of mice by 70% (at the criterion of
35%), and the biologically significant antitumor effect
persisted for 14 days (at the criterion not less than
7 days). We have also shown that TKmGM-PPT/GCV is
efficient for treatment of transplantable tumors C26 and
almost ineffective for CSC5. Thus, the efficacy of
TKmGM depends on the histological form of the tumor
and declines in the row S37 > C26 > CSC5.
Earlier, it was shown that higher GCV doses enhance
therapeutic efficacy of the HSVtk/GCV system [66].
Figure 5 Survival period of mice inoculated with A) adenocarcinoma
C26; B) cervical squamous carcinoma CSC5 after injection of
TKmGM-PPT. TKmGM (CMV-HSVtk-mGM-CSF-pGL3 construct);
PPT - polyethylenimine-polyethylene glycol-TAT peptide copolymer;
PBS – phosphate buffered saline (placebo); GCV – ganciclovir.
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dose of GCV (150 mg/kg), and TKmGM-PPT was tested
in allograft animal models at the background of GCV in-
jection at a daily dose of 150 mg/kg for 15 days (total
dose of 2.25 g/kg).Discussion
We studied the efficacy of the HSVtk/GM-CSF combin-
ation in one vector delivered by a nonviral carrier – a
PEG-PEI-TAT copolymer. This combination was tested
in vitro in various mouse and human cell lines, ex vivo,
and in vivo using mouse models. It appeared to be effi-
cient in terms of both tumor shrinkage and metastasis
inhibition. The question is whether these results are
promising for their further use in clinical practice. The
problem in that preclinical efficacy of most drugs in
mouse models is not the guarantee of positive clinical
response is now widely debated. Even among cancer
drugs that have passed Phase I testing, only 1 of 10 was
finally approved [67]. Therefore, extrapolation of the re-
sults for these models to human disease is often not
straightforward [67,68].We will try to consider this problem from the stand-
point of gene therapy prospects with respect to clinical
trials.HSVtk can be active in human tumors providing proper
delivery
HSVtk seems to be a very attractive potential drug due
to its universal mechanisms of action. It is targeted at
the cell’s replication machinery, which exists in all spe-
cies, thus making HSVtk applicable to any tumor. Re-
cent reports on preclinical cancer models demonstrated
a high potential of HSVtk when used in combination
with new therapeutic approaches [1]. One of the HSVtk
great advantages is the bystander effect that allows to
destroy not only cells transfected with the gene but also
nearby untransfected cells, thus strongly increasing the
potential efficacy [22,69,70]. Another potential advantage
of HSVtk is its ability to stimulate the immune system
to eliminate tumor cells that do not express the suicide
gene, a phenomenon which could lead to the destruction
of metastases originated from a primary tumor [19]. All
these effects are not expected to be species specific. In-
deed, we demonstrated that the HSVtk gene was trans-
lated into a functional HSVtk enzyme at a high level in
human cells. Due to the advantageous features of HSVtk,
the HSVtk/GCV was the first GDEPT system described.
A large number of experiments were performed with
this system in different types of tumors, and initial re-
sults in animal models were very promising [71]. How-
ever, the clinical trials were not so convincing, although
they are still going on [1,17,19,71-73]. The barriers on the
way of translation of preclinical models to clinical out-
comes are most probably due to specific properties of
model animal tumors and their microenvironment [74,75].
Apart from other aspects of intra- and inter-tumor vari-
ability, many authors pay great attention to a so called en-
hanced permeability and retention (EPR) phenomenon
[4,76-81]. EPR is a property of well-developed and poorly
differentiated solid tumor vasculature, the enhanced per-
meability of which allows nanoparticles of the size of up to
several hundreds of nanometers to enter the tumor inter-
stitial space, whereas the suppressed lymphatic filtration al-
lows them to stay there. Now it is becoming clear that the
EPR effect is much stronger in mouse tumors than in hu-
man patients, simply because most rodent tumors grow
much faster. This directly concerns the HSVtk/GCV sys-
tem which forms nanoparticles both in case of its delivery
by viral and nonviral particles.
Moreover, penetration of drugs into the tumor and
metastatic cells is hindered due to the properties of the
tumor microenvironment. Hence, drug uptake can be
different in animal and human tumors. Other peculiar-
ities of intratumoral barriers and the biodistribution of
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reviews.
These highly complicated multilayer systems of bar-
riers on the way of a drug to tumor cells stimulate the
search for additional means to make tumor and its me-
tastases more vulnerable to therapy. One of such means
is activators of the host immune system, such as cyto-
kines [82-84]. We used GM-CSF for this goal.
GM-CSF is a potent immunomodulator both in mice and
human: positive practice of its clinical application
Cytokines are used worldwide in clinical trials for the pur-
poses of cancer gene therapy. The database [85] contains
1264 records devoted to cancer gene therapy clinical trials.
367 (29%) of them used cytokine genes as therapeutic
agents, and 84 utilized GM-CSF. Data on synergistic activ-
ity of the suicide gene HSVtk and the immunomodulator
GM-CSF support the GM-CSF capacity to enhance thera-
peutic effect [42]. There is a general belief that although
local tumor control is important, efficient therapies to in-
crease survival rate must also target metastases. Clinically,
most cancer patients die of relapse and metastasis, and
not of the primary tumor. However, the therapeutics cap-
able of effectively preventing and targeting metastasis are
very limited [86,87]. GM-CSF is considered one of the
most effective inducers of tumor immunity [88]. It was
reported to be able to enhance most types of immune
responses [30]. The GM-CSF recombinant protein
(Sargramostim/Leukine) was approved by FDA for clinical
use. GM-CSF is extensively used in genetic engineering of
(re-)infused cells for vaccination purposes [37].
Many oncolytic viruses armed with GM-CSF are now
in clinical trials (see e.g. [26,32-35,54,89,90]). The data
available permit to hope that GM-CSF will be as effect-
ive in cancer patients as in our model systems.
Positive application of oncolytic viruses producing GM-CSF
Large tumor volume, cancer and stromal cells differently
organized in different locations of the same tumor, and
other negative factors [10,91-96] may create difficulties
for both suicide and oncolytic virus therapy. This is an
important reason for attempting to reach systemic effi-
cacy by recruiting the immune system, instead of relying
on oncolysis alone [90].
It has been already reported that several species of
oncolytic viruses producing GM-CSF were tested in clin-
ical trials and demonstrated safety, antitumor efficacy,
and tumor-specific immune activation [54,90]. It was
also shown that oncolytic virus therapies with GM-CSF
expressing vectors can induce durable responses even in
late stage solid tumors through the direct oncolysis and
induction of anticancer immunity [33,34].
A hypothesis was put forward that tumor antigens re-
leased from dying cancer cells are accessible to antigenpresenting cells which can activate cytotoxic T-lymphocytes
for killing non-infected tumor cells [19,41,90]. This im-
mune activation can be increased by locally produced
GM-CSF, leading eventually to more aggressive antitumor
immune response [90]. In case of suicide gene therapy, this
hypothesis predicts that a combination of a suicide gene
and GM-CSF within one vector will be preferable over a
combination of two independent vectors each carrying only
one of these two genes. The latter combination was tested
earlier [41].
Advantages of nonviral delivery systems
We used PEI-containing polyplexes modified with poly-
ethylene glycol (PEG) and the cell-penetrating peptide
TAT. The properties and behavior of these polyplexes in
different cell lines could be adjusted to achieve higher
transfection efficiency [57]. A detailed discussion of ad-
vantages and disadvantages of viral and nonviral delivery
systems in gene therapy can be found in recent reviews
[1,18,19,97-103]. Briefly, nonviral vectors are advanta-
geous due to low immunogenicity, practically unlimited
packaging capacity for genetic material, and simple and
low-cost production, which makes them more suitable
to large-scale production and potentially safer in clinical
use [56,98,104-106]. However, they are characterized by
low gene transfer efficiency and transient or steadily de-
clining gene expression. On the other hand, viral vectors
are characterized by low packaging capacity, relatively
high production costs and a toxicity profile that can pro-
voke inflammation and immunogenicity. Potential dangers
of viral vectors to patients, staff, and possible shedding
into the environment have resulted in rather stringent
terms of use and risk assessments. Commercial manufac-
turing of therapeutic viruses, which is the final goal of re-
search efforts, may meet serious problems and be highly
expensive. These features have led to questioning the via-
bility of virus-based approaches [55].
Keeping this in mind, it is interesting to analyze the
latest data on GDEPT systems which are now in clinical
trials according to the database “Gene therapy. Clinical
trials worldwide” provided by the Journal of Gene Medi-
cine [85], updated by July 2013.
According to the database, there are 9 Phase III, 12
Phase II and 91 Phase I ongoing clinical trials for treat-
ment of various cancers with suicide genes in various
vectors. Adenoviral, retroviral and herpes simplex type 1
viral vectors were used in 64, 66, and 11 trials, respect-
ively. Only a few trials used inexpensive delivery systems:
5 trials used naked plasmid DNA and two trials -
lipofection.
Such an evident “viral bias” is in line with the opinion
expressed by Duenas-Gonzalez and colleagues: “The high-
risk/high-reward aspect of drug discovery comprises a
greater issue in the commercial realm in terms of new-
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logical products are subject to the laws of marketing; hence,
the majority of the newer cancer products are simply cost-
prohibitive to the vast majority of patients worldwide,
which has been widely approached and reviewed” [107].Conclusions
Apart from efficacy and safety, it is desirable that each
drug should be inexpensive and affordable to a wide
range of patients. In present-day GDEPT clinical trials,
viral delivery systems dominate due to efficient trans-
fection and production of therapeutic genes. However,
safety concerns associated with immune and inflam-
matory responses as well as high cost of therapeutic vi-
ruses can limit their wide therapeutic use. In this
regard, nonviral delivery systems seem to be advanta-
geous despite lower efficiency. An important attribute
of suicide therapy is the so-called bystander effect,
which can partially compensate for the poor efficiency
due to the diffusion of intracellular toxin to neighbor-
ing tumor cells. A further increase in the efficiency of
GDEPT can be achieved by induction of antitumor im-
mune response which should also lead to the destruc-
tion of metastases.
Therefore, we designed and experimentally tested non-
viral vectors that carried both the suicide (HSVtk) and
immunomodulating (GM-CSF) genes encapsulated in-
side the envelope made of a PEG-PEI-TAT copolymer.
The vectors were administered intratumorally. We ex-
pected a synergistic effect of the two therapeutic genes
because of a high local concentration of both tumor anti-
gens from destroyed cancer cells and the cytokine recruit-
ing immune antigen-presenting cells. In fact, we found that
the simultaneous intracellular expression of the HSVtk and
GM-CSF genes had a greater antitumor effect than the ex-
pression of HSVtk or GM-CSF alone. In particular, the
treatment of animals with the TKmGM-PPT system was, in
most cases, able to inhibit the growth of tumor and metas-
tases and increase lifespan. Thus, the data obtained here
show that quite efficient antitumor effects can be achieved
using a simple and low toxic nonviral carrier – a PEG-PEI
copolymer, providing that the vector contains both the sui-
cide and immunomodulating gene. Study of the TKmGM-
PPT toxicity demonstrated safety of this complex. The
observed toxic reactions in animals were weak and fully re-
versible (to be published elsewhere). We believe that the re-
sults obtained are promising enough to move towards
clinical trials.
Vector constructions used in the work: TKmGM – CMV-
HSVtk-mGM-CSF-pGL3 construct, TKhGM – CMV-
HSVtk-hGM-CSF-pGL3 construct, TK – CMV-HSVtk-pGL3
construct, hGM – CMV-hGM-CSF-pGL3 construct,
mGM – CMV-mGM-CSF-pGL3 construct, TKGM –collective designation for CMV-HSVtk-mGM-CSF-pGL3
and CMV-HSVtk-hGM-CSF-pGL3 construct.
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Additional file 2: Figure S2. Biological activity of HSVtk expressed from
the TK and TKmGM constructs transfected with LFA.
Additional file 3: Table S1. In vitro cytotoxic effect of TKGM complexed
with PPT or LFA, in combination with GCV.
Additional file 4: Table S2. In vivo cytotoxic effect of TK, mGM or
TKmGM complexed with PPT or LFA in combination with or without
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Additional file 5: Figure S3. Survival period of sarcoma 37-bearing mice
after injection of TK-LFA, mGM-LFA and TKmGM-LFA with or without
ganciclovir.
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